Biologics in COVID-19 So Far: Systematic Review
This systematic review aimed to reevaluate the available evidence of the use of biologics as treatment candidates for the treatment of severe and advanced COVID-19 disease; what are the rationale for their use, which are the most studied, and what kind of efficacy measures are described? A search th...
Main Authors: | Milton Arias, Henry Oliveros, Sharon Lechtig, Rosa-Helena Bustos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/7/783 |
Similar Items
-
Impact of social distancing from the COVID-19 pandemic on the immuno-inflammatory response of older adults
by: Giulia Beletato Nery, et al.
Published: (2024-01-01) -
Interleukin‐29 profiles in COVID‐19 patients: Survival is associated with IL‐29 levels
by: Zahra Fallah Vastani, et al.
Published: (2022-03-01) -
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion
by: Gianni Gori Savellini, et al.
Published: (2022-06-01) -
T-cell responses to SARS-CoV-2 in unexposed South African women [version 2; peer review: 2 approved]
by: Marta C. Nunes, et al.
Published: (2022-07-01) -
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
by: Sandra Rodríguez, et al.
Published: (2020-08-01)